Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,032 across all filing types
Latest filing 2021-03-31 Regulatory Filings
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Achilles update on IPO
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number' and contains information about a portfolio company (Achilles) announcing its Initial Public Offering (IPO) pricing. The text explicitly mentions that this information is provided by RNS, the news service of the London Stock Exchange, and that RNS is approved by the Financial Conduct Authority (FCA) as a Primary Information Provider. This structure and source strongly indicate a regulatory news service announcement. Since the content is a specific corporate update (an IPO pricing announcement by a portfolio company) that is being disseminated via the official regulatory channel (RNS), and it doesn't fit neatly into the other specific categories like 10-K, ER, or CAP (which usually detail the financing terms or results themselves), the most appropriate classification is the general regulatory filing/announcement category, RNS.
2021-03-31 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is explicitly labeled with an 'RNS Number' and contains the header 'Notification of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs") and Connected Persons'. This type of filing reports insider trading or director dealings. The definition for Director's Dealing (DIRS) covers 'Report of personal share transactions by company directors and executives (insider trades)'. Although the document is distributed via RNS, the specific content is a Director's Dealing report, making DIRS the most accurate classification over the general RNS fallback. The document length is short (3775 chars), but it contains the full details of the transactions, not just an announcement that a report is available, thus it is not an RPA.
2021-03-30 English
Gyroscope announces additional financing plans
Capital/Financing Update Classification · 97% confidence The document is very short (3331 characters) and begins with an 'RNS Number' and is distributed by 'RNS, the news service of the London Stock Exchange'. The content announces that a portfolio company ('Gyroscope Therapeutics') 'announces additional financing plans' and 'expects to consider additional capital raising options this year, which could include an initial public offering'. This is a formal regulatory announcement regarding potential future financing activities, not the detailed financing document itself. Given the source (RNS) and the nature of the announcement (a brief update on potential capital raising), it fits best under the general regulatory announcement category, RNS, as it is not a specific financing document (CAP) but rather a notification of intent/plans.
2021-03-26 English
Syncona cornerstones $148m Series C in Gyroscope
M&A Activity Classification · 99% confidence The document begins with 'RNS Number : 6222T' and includes the standard disclaimer about RNS being approved by the Financial Conduct Authority (FCA) as a Primary Information Provider. The content details a significant investment ($42.3 million) by Syncona into Gyroscope Therapeutics as part of a Series C Financing round. This type of announcement, which is a material corporate event but not a full financial report (like 10-K or IR) or a specific proxy/remuneration filing, fits best under the general regulatory announcement category, especially given the RNS header. Since it is a specific announcement of a financing/capital event, 'CAP' (Capital/Financing Update) is highly relevant, but because it is distributed via the RNS system and is a general material announcement, 'RNS' (Regulatory Filings) is also a strong candidate. Given the specific nature of the news (a major financing round), 'CAP' is the most precise classification for the *content*, while 'RNS' describes the *distribution mechanism*. Since 'CAP' is a defined category for financing activities, it is preferred over the general 'RNS' fallback. The document length (8408 chars) is substantial, indicating it is the primary announcement, not just a notice of publication (RPA).
2021-03-26 English
Update on Achilles’ proposed IPO
Share Issue/Capital Change Classification · 99% confidence The document is an official announcement released via RNS (RNS Number: 5071T) from Syncona Limited on March 25, 2021. The content explicitly discusses a portfolio company, Achilles Therapeutics, filing an amended registration statement on Form F-1 with the SEC for a proposed Initial Public Offering (IPO) in the United States. This announcement details the indicative pricing range, the number of ADSs, and the expected gross proceeds. Since the document is an announcement about a capital market activity (an IPO filing) and is distributed through a regulatory news service (RNS), it relates to financing activities. However, the core subject is the filing of a registration statement for a public offering, which falls under Capital/Financing Update (CAP). Given that it is a brief announcement (4727 chars) reporting on the filing of a prospectus/registration statement rather than being the prospectus itself, it could potentially be RPA or RNS. But because the subject matter is specifically about fundraising/capital structure change (IPO), CAP is the most precise fit among the specific categories. It is not a general regulatory filing (RNS) or a report publication announcement (RPA) in the sense of announcing a periodic report like a 10-K or IR.
2021-03-25 English
Autolus Reports Full Year 2020 Financial Results
Earnings Release Classification · 95% confidence The document is an RNS (Regulatory News Service) announcement issued by Syncona Limited. It serves as a notification that its portfolio company, Autolus Therapeutics, has released its full-year 2020 financial results. The document contains the headline, a summary of the financial results, operational highlights, and key pipeline updates for Autolus. Because this is a regulatory announcement relaying the financial results of a subsidiary rather than the primary financial report of the filing entity itself, and it follows the standard format of a press release/regulatory announcement, it is classified as an Earnings Release (ER). FY 2020
2021-03-04 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.